New Desensitization Strategy: Daratumumab for Highly Sensitized Pediatric Heart Transplant Candidate

Transplantation. 2023 Oct 1;107(10):e271-e272. doi: 10.1097/TP.0000000000004719. Epub 2023 Sep 25.

Authors

Nathanya Baez Hernandez^{1

2}, Ryan Butts^{1

2}, Laura Radel^{1

2}, Maria Bano^{1

2}, Jodie Lantz^{1

2}, Ryan Davies^{1

2

3}, Chantale Lacelle⁴, Mehreen Iqbal^{1

2}, Tracey Ellimuttil⁵

Affiliations

¹ Department of Pediatric Cardiology, Children's Health, Dallas, TX.
² Division of Pediatrics, University of Texas Southwestern, Dallas, TX.
³ Department of Cardiovascular and Thoracic Surgery, UT Southwestern Medical Center, Dallas, TX.
⁴ Department of Pathology, UT Southwestern Medical Center, Dallas, TX.
⁵ Department of Pharmacy, Children's Health, Dallas, TX.

PMID: 37749815
DOI: 10.1097/TP.0000000000004719

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal* / therapeutic use
Child
Desensitization, Immunologic*
Heart Transplantation*
Humans

Substances

Antibodies, Monoclonal
daratumumab